Propanc Biopharma To File CTA In Australia For Phase 1b Study In 30–40 Advanced Cancer Patients; Plans Two Phase 2 Studies In Pancreatic And Ovarian Cancers With 60 Patients Each

Benzinga Newsdesk www.benzinga.com Neutral 83.5%

Neg 0% Neu 83.5% Pos 0%

Comments

No comments yet. Be the first!